Movement Disorders and Neurodegenerative Diseases
A section of Neurology International (ISSN 2035-8377).
Section Information
Neurodegenerative diseases are characterized by the slow and irreversible loss of selectively vulnerable neuronal populations. The formation of abnormal protein aggregates is a key pathological feature in many of these diseases. The hallmark intracellular proteins undergoing pathological change and aggregation are tau (in Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia tau-subtype), alpha-synuclein (in Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy), and TDP-43 and FUS (in amyotrophic lateral sclerosis and frontotemporal dementia subtypes), whereas beta-amyloid (in Alzheimer's disease) and prion protein (in Creutzfeldt–Jakob disease and other prion diseases) accumulate in the extracellular space. Clinically, they present with a movement disorder that causes abnormal or involuntary movements, and/or with neurocognitive impairment leading to dementia. Movement disorders, like Parkinson’s disease, in addition to motor symptoms, often present with cognitive and psychiatric impairments leading to Parkinson’s disease dementia, whereas dementias like Alzheimer's disease, although not a typical movement disorder, can also lead to motor dysfunction in its later stages. Neurodegenerative disease may be familial with disease-causing mutations, or apparently sporadic often with predisposing genetic alterations. Huntington’s disease, Friedreich’s ataxia, fragile X-associated tremor/ataxia syndrome, and certain spinocerebellar ataxias are autosomal dominant triplet expansion diseases. Movement disorders may have non-neurodegenerative causes like genetic, endocrine, metabolic, toxic, and infectious. Overall, the etiology of these diseases is complex and has a significant impact on the quality of life of patients, posing a substantial burden on healthcare systems and society. The Section on “Movement Disorders and Neurodegenerative Diseases” will explore research in the diagnosis, pathogenesis, treatment, and clinical management of these conditions.
Keywords
- Aging
- Alzheimer's disease
- Amyloid plaques
- Amyotrophic lateral sclerosis
- Ataxia
- Dementia
- Dystonia
- Huntington's disease
- Motor neuron diseases
- Movement disorders
- Neurodegeneration
- Neurodegenerative diseases
- Parkinson's disease
- Prion diseases
- Progressive supranuclear palsy
- Synucleinopathies
- Tauopathies
- TDP-43
- Tremor
Editorial Board
Click here to see the Section Editorial Board of "Movement Disorders and Neurodegenerative Diseases".
Special Issues
Following special issues within this section are currently open for submissions:
- Innovations in Acute Stroke Treatment, Neuroprotection, and Recovery (Deadline: 30 October 2025)
- Biomarker Research in Neuromuscular Diseases (Deadline: 30 November 2025)
- Towards an All-Inclusive Paradigm for Acute Stroke Treatment—Challenges and Innovations (Deadline: 30 November 2025)
- Advances in Molecular Mechanisms of Neurodegenerative Diseases (Deadline: 30 November 2025)
- Pathogenesis and Therapeutic Intervention of Alzheimer's Disease (Deadline: 31 December 2025)
- Mitochondria in Neurodegenerative Disease: Mechanisms and Therapeutic Targets (Deadline: 31 December 2025)
- Early Biomarker Identification and Treatment Strategy for Alzheimer's Disease (Deadline: 31 December 2025)
- Molecular and Cellular Research of Neuroprotection and Neurodegeneration (Deadline: 30 January 2026)
- Neurotrophic Factors: A Focus on the Therapeutic Level (Deadline: 30 January 2026)
- Advances in Novel Treatment and Rehabilitation for Strokes (Deadline: 31 January 2026)
- Molecular Research of CNS Diseases and Neurological Disorders (Deadline: 28 February 2026)
- Molecular Mechanisms and Treatment of Parkinson’s Disease (Deadline: 31 March 2026)
- Drug Treatment of Epilepsy (Deadline: 31 March 2026)
Topical Collections
Following topical collections within this section are currently open for submissions:
